Home › Funds › Newtyn Management, LLC › MREO

Newtyn Management, LLC position in MREO

MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS · Health Care

Newtyn Management, LLC reported holding 3,000,000 shares of MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS) in its Q2 2026 13F filing — a position valued at US$953K, representing 0.12% of its reported portfolio and ranking #33 among its reported holdings. Newtyn Management, LLC has disclosed MREO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)3.00M sh
Reported value held$953.10K
Portfolio Weight0.12%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Newtyn Management, LLC's MREO position evolved

Newtyn Management, LLC first disclosed a stake in MREO in Q4 2025 at 224,622 shares (US$94K). The position peaked in Q1 2026 at 7,079,056 shares, worth US$2.3M. Across 3 filings, Newtyn Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,000,000 shares valued at US$953K — a reduction of -4,079,056 shares quarter over quarter.. Notable position changes include a 3052% increase in Q1 2026 (shares fell 4% over the following quarter), a 58% trim in Q2 2026 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 224.62K $93.60K New
Q1 2026 7.08M $2.34M Add
Q2 2026 3.00M $953.10K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MREO and 13F data

MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS) is a Health Care company. 4 other funds we track also report a position in MREO — the largest reported positions include Defilade Capital Management, L.P. (US$2.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MREO

All MREO fund holders →

FAQ

How long has Newtyn Management, LLC held MREO?

Newtyn Management, LLC has disclosed MREO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Newtyn Management, LLC's current position in MREO?

As of Q2 2026, Newtyn Management, LLC holds 3.00M shares of MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS), valued at $953.10K, representing 0.12% of its reported portfolio and ranking #33.

Has Newtyn Management, LLC been buying or selling MREO?

In the latest 13F filing (Q2 2026), Newtyn Management, LLC reduced its position in MREO. The position peaked in Q1 2026 at 7.08M shares.

Which other funds hold MREO?

Other major institutional holders of MREO include Defilade Capital Management, L.P., among 4 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.